Monday, May 11, 2026

Did Bill Gates’ Trip To China Portend The Emergence Of A Virus Such As MERS?

Date:

“COVID-19, AIDS, SARS, MERS, ZIKA and Bird Flu…they all have something in common: the hand of Dr. Anthony Fauci. Every pandemic is exploited to propagate misinformation about vaccines and other treatments – this must not be tolerated any longer.”

Celia Farber is an investigative print reporter who staked out one of the most dangerous and unpopular stories of the last century: How the US government uses imaginary “viruses” as instruments of psychological terror, war, and profit.

Related Article:

Unnatural Epidemics: The trip of Bill Gates to China means an upcoming virus ‘LEAK’ might be caused by climate change, right?

Image-Chinese Foreign Ministry/Twitter

What is MERS? According to World Health Organisation (WHO) MERS-CoV (Middle Eastern Respiratory Syndrome Coronavirus).

An overview of how mRNA technology has developed in communist China

Summary: Communist China has been planning mRNA technology development since long ago. The regime acquired mRNA technology in 2016 and engaged in MERS mRNA vaccine development in 2017.

On March 22, 2023, the mRNA Covid vaccine by CSPC Pharmaceutical Group was granted Emergency Use Authorization in Communist China, eleven months after the start of clinical trials. [1] This news aroused great interests worldwide. What is Communist China’s research and development capacity in mRNA technology? This article will provide an overview of Communist China’s mRNA technology development.

Early trailblazers in the mRNA field included Fudan University, the Academy of Military Medical Sciences (AMMS), CanSino Bio, and about nine startups—Abogen Biosciences, LiveRNA (acquired by AIM Bio), RNACure Biopharma, InnoRNA, ImmoRNA Biotechnology, Rhegen Biomedical Technology, Longuide, Stemirna Therapeutics, TheraMab Bioscience [2]. Some newcomers later joined the sector, such as Rongcan Biotech, RiboBio, YolTech Therapeutics, CirCode Bio, Everest Medicines, CSPC Pharmaceutical Group, and Sinopharm Group.

Completely contrary to public perceptions, Communist China had been preparing for mRNA technology research for years. During an interview, the founder of RNACure Biopharma Yu Hang suggested he witnessed the growth of Moderna and planned to enter the mRNA field in 2016 after being inspired. [3] Founded by Dr. Li Hangwen in 2016, Stemirna Therapeutics was the first company to bring mRNA technology into China, and this company began development of MERS (Middle East Respiratory Syndrome) and influenza mRNA vaccines in 2017. [4] Fudan University Professor Lin Jinzhong, who co-founded the Shanghai mRNA Innovation and Translation Center, began research on mRNA technology in 2017. [5] CanSino Bio started mRNA research in 2018 and developed a software platform to optimize mRNA sequences. [6]

Screenshot 1 of Stemirna Therapeutics’ company website. [4] The webpage was deleted.

Screenshot 2 of Stemirna Therapeutics’ company website. [4]

Communist China conducted human clinical trials of mRNA therapeutics since long ago. A timeline on the website of Stemirna Therapeutics indicated it carried out clinical trials of an anti-cancer mRNA vaccine on cancer patients in 2018. (The company’s website was suddenly deleted a few days ago). [4] If it started clinical trials of mRNA therapeutics at such an early time, did it discover any adverse effects?

Fudan University is the first university in China to research on mRNA technology. [5] Several bellwethers in this field are from Fudan University. For example, founder of Fosun Pharma Guo Guangchang, CEO of Junshi Pharma Li Ning, and Director of the National Infectious Disease Medical Center Zhang Wenhong (nicknamed China’s Fauci) are all Fudan University alumni. Lin Jinzhong is a professor at Fudan University. [7] Zhang Wenhong often advocates for Covid jabs, but he is also listed as an expert at the Shanghai mRNA Innovation and Translation Center [5]—he is also a link on the vaccine production chain.

Some Chinese pharmaceutical companies relied on foreign technology to develop mRNA Covid vaccines. The most well-known example is the agreement between BioNTech and Fosun Pharma. In addition, in May 2020, CanSino Bio bought the technology of Canadian company Precision NanoSystems to develop an mRNA vaccine. [6] In September 2021, Everest Medicines licensed in mRNA technology from another Canadian company Providence Therapeutics. [8] Besides relying on foreign technology, Communist China also possesses robust research capability on mRNA technology. There are many mRNA tech companies in Communist China, and its research capacity is as strong as Western big pharma.

To some sense, Communist China’s mRNA technology is obtained from the United States or Western countries. Many top scientists have work experiences in Western research institutions or companies. To name a few, founder of Stemirna Therapeutics Li Hangwen earned his PhD degree at the MD Andersen Cancer Center [4, 9]. Fudan University professor Lin Jinzhong was a postdoc at Yale University [10]. Founder of InnoRNA Li Linxian’s postdoc mentor at MIT was the founder of Moderna [9]. Founder of ImmoRNA Biotechnology Wang Zihao used to work at GSK [11]. For Rongcan Biotech founder Zhang Xueqing, her mentor was also the founder of Moderna [12, 13]. Founder of TheraMeb Bioscience Wu Chenyan used to be a senior scientist at Pfizer [14]. Founder of Abogen Biosciences Ying Bo was a former employee of Moderna [15]. These scientists made further improvements upon Western technology and claimed to own intellectual property. (Wu Chenyan was indicted in the United States for stealing Pfizer’s mRNA data, though [16].)

Communist China’s mRNA startups were established at a strange time point. Six of the nine early mRNA vaccine startups were founded in 2019, in the months leading up to the Covid pandemic. (They are Abogen Biosciences, LiveRNA, RNACure Biopharma, InnoRNA, ImmoRNA Biotechnology, and Rhegen Biomedical Technology.) [2] In most of 2019 before the pandemic, mRNA technology was an obscure and unprofitable field since vaccine demand was low. So many mRNA vaccine companies popped up together in Communist China in 2019, and this pattern probably indicates some kind of pre-planning. Then the pandemic erupted afterward.

Founding time of early mRNA startups. Image source: [2]

Some tech startups were tied to Communist China’s military. Abogen Biosciences partnered with Walvax Biotechnology and the Academy of Military Medical Sciences (AMMS) to create ARCoV vaccine, which is Communist China’s first domestic mRNA Covid vaccine to enter clinical trials [14]. LiveRNA collaborated with AMMS in mRNA vaccine development [14]. TheraMeb Bioscience carried out animal studies on mRNA Covid vaccine at the AMMS [14]. CanSino Bio also worked with Communist China’s military.

Some startups were supported by giant capital funds. Abogen Biosciences had undergone several rounds of fundraising from investors, one of which was Boyu Investment [17]. At early phase, the sole sponsor of Rhegen Biomedical Technology was Sequoia China [18].

Besides the Fosun Pharma’s licensed BioNTech vaccine, six brands of mRNA Covid vaccines have entered clinical trials. The six brands are Abogen-Walvax-AMMS partnership, Stemirna Therapeutics, LiveRNA, RiboBio-Agena Bioscience partnership, CSPC Pharmaceutical Group, and CanSino Bio. [19] The CSPC vaccine is already granted EUA.

Believe or not, Communist China developed mRNA Covid vaccines at lightning speed. The country has developed several types of mRNA vaccine within a few months of the Covid outbreak, although the progress of clinical trials and public usage was slow. In spring 2020, founder of LiveRNA Peng Yucai designed an mRNA vaccine candidate within eight days, and the design was submitted to government agencies for animal tests on February 1, 2020. [14] Abogen’s ARCoV vaccine was approved for phase I clinical trials in June 2020. [20] Lin Jinzhong and RNACure Biopharma used mRNA vaccine to produce virus-like particles and submitted their research results to the journal Cell Research in June 2020 [21], but Lin already attained experimental success in February 2020 [3].

A key feature of Communist China’s domestic mRNA vaccines is stability under high temperature. Both Abogen’s ARCoV vaccine and CSPC Group’s SYS6006 vaccine could be stored at 2-8 degrees Celsius for months, obviating the need for freezer storage [22, 23]. Rhegen Biomedical Technology made further progress by the invention of a lyophilized mRNA vaccine dry powder that is stable at room temperature (25 degrees Celsius) [24, 25]. In my opinion, such vaccines have pros and cons. The upside is that chemicals in the vaccines are stable and resistant to degradation, and are therefore convenient for transportation and storage. But the downside is whether the chemicals are bio-degradable after injection into the human body. Will the chemical residues cause adverse effects if they cannot be removed in the human body?

Even some Chinese media questioned the safety of domestically produced mRNA vaccines. The phase I clinical trials report of Abogen’s ARCoV concluded the vaccine was safe and effective. However, careful scrutiny of the experimental data revealed points of concern. About 90% of the 15-microgram dosage group reported adverse effects, of which 85% were fevers. The 25-microgram dosage group had 100% fever rate [26, 27]. This data proves that mRNA vaccines could be harmful for humans. Moreover, during an interview, founder of Longuide Zhang Longgui explained that lipid nanoparticles (LNP) exhibit dosage-dependent toxicity and are therefore unsuitable for high-dose and long-time injections [28]. Anyway, mRNA vaccines are somewhat toxic.

The pharmaceutical executives sometimes attended scientific seminars together. On March 11, 2021, the Shanghai Biopharmaceutics Industry Association hosted the mRNA Pharmaceutical Innovation Seminar. To name a few, guests of this event were Fosun Pharma’s President of Global R&D Hui Aimin, Professor Lin Jinzhong of Fudan University, founder of Stemirna Therapeutics Li Hangwen, and founder of RNACure Biopharma Yu Hang. [29]

These mRNA companies excel in different technological strong points. Some are even unicorns with unique technology, at least in China. For instance, (1) Stemirna’s mRNA vaccines use Lipopolyplex (LPP) instead of lipid nanoparticles (LNP) for delivery. In an LPP, polymers first encapsulate the mRNA to form a core that is in turn coated by lipid, so that there are two layers of coatings. [19] (2) ImmoRNA Biotechnology is the only company in China that develops self-replicating mRNA, which could self-replicate inside cells like viruses, as the name suggests. Self-replicating mRNA is a very potent drug. [19] (3) Rhegen Biomedical Technology pioneered lyophilized mRNA vaccine dry powder that is stable at room temperature (25 degrees Celsius) [19] (4) YolTech Therapeutics specializes in combining gene-editing CRISPR-Cas9 technology with mRNA technology, employing lipid nanoparticles to deliver gene-editing mRNA. [19] (5) CirCode Bio develops circular RNA that is resistant to degradation. [30]

No matter how advanced the technology is, mRNA vaccines are NOT free of adverse effects. Don’t take the mRNA jabs if you want a long and healthy life.

References List (Sorry, most of the references are webpages written in Chinese): Click Here to Copy and Paste

不是沃森生物! 石药集团拿下首款国产mRNA新冠疫苗, 从临床到获批11个月。凤凰新闻。2023-03-23

https://finance.ifeng.com/c/8OOJXl5fV2a

2. 国产mRNA疫苗现状, 嘉晨西海成”海王”, 国内mRNA企业不超10家。搜狐网。2021-07-26

https://www.sohu.com/a/479594694_121035734

经纬人物No.21-蓝鹊生物创始人俞航。雪球网。2021-08-27

https://xueqiu.com/7211544918/195815828

斯微生物官网 (网页突然被删除)

https://www.stemirna.com/History/list.aspx

张江mRNA国际创新中心官网

https://www.shmitc.org.cn/aboutus/superiority

详解康希诺和石药的新冠mRNA疫苗及其辅料国产化。雪球网。2022-04-28

https://xueqiu.com/1036022495/218700743

复星集团到底干什么的? 这么有钱? 知乎网。2022-09-24

https://www.zhihu.com/question/280582791/answer/2641787247?utm_id=0

履新云顶新耀后, 罗永庆首谈心路历程和公司规划。腾讯新闻。2023-01-06

https://view.inews.qq.com/k/20230106A09Y7Z00?no-redirect=1&web_channel=wap&openApp=false

时代的箭头: mRNA疫苗背后的中国力量。中国医药创新促进会。2021-06-08

http://www.phirda.com/artilce_24549.html?cId=1

林金钟教授简介。复旦大学官网。

https://life.fudan.edu.cn/b3/74/c28175a308084/page.htm

嘉晨西海官网

https://www.immorna.com/cn/about.html

LNP专利, mRNA制药产业的痛点。雪球网。2021-12-16

https://xueqiu.com/4376152234/206091927

章雪晴教授简介。上海交大官网。

https://pharm.sjtu.edu.cn/szdy/2639.html

mRNA三大巨头撑起约6000亿市值, 国内mRNA公司一览。雪球网。2020-12-27

https://xueqiu.com/5603603160/166878330

15. 艾博生物创始人英博: 不只新冠疫苗, 立足mRNA技术平台的产业变革。雪球网。2021-09-06

https://xueqiu.com/1916655314/196851670

一家mRNA创新药企的猝死之谜。网易。2022-05-27

https://m.163.com/dy/article/H8DCUUL90514BJBO.html?spss=adap_pc

艾博生物官网

https://www.abogenbio.com/news2021/140.html

瑞吉生物, 敢做创业路上的孤勇者-红杉早期医疗投资特写。搜狐网。2022-09-09

https://www.sohu.com/a/583568130_121119001

全面梳理国内mRNA研发管线。健康界。2022-04-13

https://www.cn-healthcare.com/articlewm/20220414/wap-content-1338297.html

Zhang NN, and et al. A Thermostable mRNA Vaccine against COVID-19. Cell. 2020 Sep 3;182(5):1271-1283.e16.

doi: 10.1016/j.cell.2020.07.024. Epub 2020 Jul 23. PMID: 32795413; PMCID: PMC7377714.

https://pubmed.ncbi.nlm.nih.gov/32795413/

Lu J, and et al. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Res. 2020 Oct;30(10):936-939.

doi: 10.1038/s41422-020-00392-7. Epub 2020 Aug 17. PMID: 32801356; PMCID: PMC7429369.

https://pubmed.ncbi.nlm.nih.gov/32801356/

Zhao H, and et al. Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates. Signal Transduct Target Ther. 2021 Dec 24;6(1):438.

doi: 10.1038/s41392-021-00861-4. PMID: 34952914; PMCID: PMC8703211.

https://pubmed.ncbi.nlm.nih.gov/34952914/

康希诺, 石药集团mRNA疫苗分别获批临床, 盘点国内mRNA疫苗研发公司。健康界。2022-04-06

https://www.cn-healthcare.com/articlewm/20220405/wap-content-1334712.html

Ai L, and et al. Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2. Cell Discov. 2023 Jan 23;9(1):9. doi: 10.1038/s41421-022-00517-9. PMID: 36683074; PMCID: PMC9868121.

https://pubmed.ncbi.nlm.nih.gov/36683074/

全球首款冻干mRNA疫苗, 来自中国团队, 可在25度下长期稳定。健康界。2022-02-19

https://www.cn-healthcare.com/articlewm/20220215/wap-content-1314995.html

艾博生物新冠疫苗合作方沃森生物”牵手”新伙伴, 公司回应为完善产品布局。每日经济新闻。2022-01-29

https://m.nbd.com.cn/articles/2022-01-29/2111710.html

Chen GL, and et al. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Microbe. 2022 Mar;3(3):e193-e202. doi: 10.1016/S2666-5247(21)00280-9. Epub 2022 Jan 24. PMID: 35098177; PMCID: PMC8786321.

https://pubmed.ncbi.nlm.nih.gov/35098177/

癌细胞可一针清除? mRNA引爆又一场疫苗革命, 四年前无投资者看好。新浪财经。2022-10-28

https://finance.sina.cn/2022-10-28/detail-imqmmthc2447288.d.html?from=wap

mRNA专家齐聚! 快来看mRNA药物创新论坛嘉宾阵容和日程。药时代。2021-03-09

https://www.drugtimes.cn/2021/03/09/6aa0d5a6bc/

环码生物官网

http://m.circodebio.cn/

Source: Gnews,Twitter, UPI(Image)

Also Read:

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Why Governments are Saying “No” to the Cashless Future 

For decades, the narrative surrounding the global economy suggested that physical currency was a dying relic of a...

Driven by lust for power, Rahul Gandhi has trapped the Congress

Dreaming of power, Rahul Gandhi has taken steps that ultimately prove self-defeating for the Congress party. From the...

Rahul Gandhi wants this leader to be the Chief Minister of Kerala, a poster war has erupted amid discussions.

The Congress-led UDF alliance in Kerala is struggling to select a Chief Minister. A series of meetings are...

The process for obtaining Aadhaar cards for children has changed, with biometric authentication becoming mandatory

The central government has made some changes to the process for obtaining Aadhaar cards for children. These changes...
news-1701

sabung ayam online

yakinjp

yakinjp

rtp yakinjp

slot thailand

yakinjp

yakinjp

yakin jp

yakinjp id

maujp

maujp

maujp

maujp

sabung ayam online

sabung ayam online

judi bola online

sabung ayam online

judi bola online

slot mahjong ways

slot mahjong

sabung ayam online

judi bola

live casino

sabung ayam online

judi bola

live casino

SGP Pools

slot mahjong

sabung ayam online

slot mahjong

SLOT THAILAND

berita 128000726

berita 128000727

berita 128000728

berita 128000729

berita 128000730

berita 128000731

berita 128000732

berita 128000733

berita 128000734

berita 128000735

berita 128000736

berita 128000737

berita 128000738

berita 128000739

berita 128000740

berita 128000741

berita 128000742

berita 128000743

berita 128000744

berita 128000745

berita 128000746

berita 128000747

berita 128000748

berita 128000749

berita 128000750

berita 128000751

berita 128000752

berita 128000753

berita 128000754

berita 128000755

artikel 128000821

artikel 128000822

artikel 128000823

artikel 128000824

artikel 128000825

artikel 128000826

artikel 128000827

artikel 128000828

artikel 128000829

artikel 128000830

artikel 128000831

artikel 128000832

artikel 128000833

artikel 128000834

artikel 128000835

artikel 128000836

artikel 128000837

artikel 128000838

artikel 128000839

artikel 128000840

artikel 128000841

artikel 128000842

artikel 128000843

artikel 128000844

artikel 128000845

artikel 128000846

artikel 128000847

artikel 128000848

artikel 128000849

artikel 128000850

article 138000756

article 138000757

article 138000758

article 138000759

article 138000760

article 138000761

article 138000762

article 138000763

article 138000764

article 138000765

article 138000766

article 138000767

article 138000768

article 138000769

article 138000770

article 138000771

article 138000772

article 138000773

article 138000774

article 138000775

article 138000776

article 138000777

article 138000778

article 138000779

article 138000780

article 138000781

article 138000782

article 138000783

article 138000784

article 138000785

article 138000816

article 138000817

article 138000818

article 138000819

article 138000820

article 138000821

article 138000822

article 138000823

article 138000824

article 138000825

article 138000826

article 138000827

article 138000828

article 138000829

article 138000830

article 138000831

article 138000832

article 138000833

article 138000834

article 138000835

article 138000836

article 138000837

article 138000838

article 138000839

article 138000840

article 138000841

article 138000842

article 138000843

article 138000844

article 138000845

article 138000786

article 138000787

article 138000788

article 138000789

article 138000790

article 138000791

article 138000792

article 138000793

article 138000794

article 138000795

article 138000796

article 138000797

article 138000798

article 138000799

article 138000800

article 138000801

article 138000802

article 138000803

article 138000804

article 138000805

article 138000806

article 138000807

article 138000808

article 138000809

article 138000810

article 138000811

article 138000812

article 138000813

article 138000814

article 138000815

story 138000816

story 138000817

story 138000818

story 138000819

story 138000820

story 138000821

story 138000822

story 138000823

story 138000824

story 138000825

story 138000826

story 138000827

story 138000828

story 138000829

story 138000830

story 138000831

story 138000832

story 138000833

story 138000834

story 138000835

story 138000836

story 138000837

story 138000838

story 138000839

story 138000840

story 138000841

story 138000842

story 138000843

story 138000844

story 138000845

article 138000726

article 138000727

article 138000728

article 138000729

article 138000730

article 138000731

article 138000732

article 138000733

article 138000734

article 138000735

article 138000736

article 138000737

article 138000738

article 138000739

article 138000740

article 138000741

article 138000742

article 138000743

article 138000744

article 138000745

article 208000456

article 208000457

article 208000458

article 208000459

article 208000460

article 208000461

article 208000462

article 208000463

article 208000464

article 208000465

article 208000466

article 208000467

article 208000468

article 208000469

article 208000470

journal-228000376

journal-228000377

journal-228000378

journal-228000379

journal-228000380

journal-228000381

journal-228000382

journal-228000383

journal-228000384

journal-228000385

journal-228000386

journal-228000387

journal-228000388

journal-228000389

journal-228000390

journal-228000391

journal-228000392

journal-228000393

journal-228000394

journal-228000395

journal-228000396

journal-228000397

journal-228000398

journal-228000399

journal-228000400

journal-228000401

journal-228000402

journal-228000403

journal-228000404

journal-228000405

article 228000376

article 228000377

article 228000378

article 228000379

article 228000380

article 228000381

article 228000382

article 228000383

article 228000384

article 228000385

article 228000386

article 228000387

article 228000388

article 228000389

article 228000390

article 228000391

article 228000392

article 228000393

article 228000394

article 228000395

article 228000396

article 228000397

article 228000398

article 228000399

article 228000400

article 228000401

article 228000402

article 228000403

article 228000404

article 228000405

article 228000406

article 228000407

article 228000408

article 228000409

article 228000410

article 228000411

article 228000412

article 228000413

article 228000414

article 228000415

article 228000416

article 228000417

article 228000418

article 228000419

article 228000420

article 228000421

article 228000422

article 228000423

article 228000424

article 228000425

article 228000426

article 228000427

article 228000428

article 228000429

article 228000430

article 228000431

article 228000432

article 228000433

article 228000434

article 228000435

article 238000461

article 238000462

article 238000463

article 238000464

article 238000465

article 238000466

article 238000467

article 238000468

article 238000469

article 238000470

article 238000471

article 238000472

article 238000473

article 238000474

article 238000475

article 238000476

article 238000477

article 238000478

article 238000479

article 238000480

article 238000481

article 238000482

article 238000483

article 238000484

article 238000485

article 238000486

article 238000487

article 238000488

article 238000489

article 238000490

article 238000491

article 238000492

article 238000493

article 238000494

article 238000495

article 238000496

article 238000497

article 238000498

article 238000499

article 238000500

article 238000501

article 238000502

article 238000503

article 238000504

article 238000505

article 238000506

article 238000507

article 238000508

article 238000509

article 238000510

article 238000511

article 238000512

article 238000513

article 238000514

article 238000515

article 238000516

article 238000517

article 238000518

article 238000519

article 238000520

update 238000492

update 238000493

update 238000494

update 238000495

update 238000496

update 238000497

update 238000498

update 238000499

update 238000500

update 238000501

update 238000502

update 238000503

update 238000504

update 238000505

update 238000506

update 238000507

update 238000508

update 238000509

update 238000510

update 238000511

update 238000512

update 238000513

update 238000514

update 238000515

update 238000516

update 238000517

update 238000518

update 238000519

update 238000520

update 238000521

sumbar-238000396

sumbar-238000397

sumbar-238000398

sumbar-238000399

sumbar-238000400

sumbar-238000401

sumbar-238000402

sumbar-238000403

sumbar-238000404

sumbar-238000405

sumbar-238000406

sumbar-238000407

sumbar-238000408

sumbar-238000409

sumbar-238000410

news-1701